Resource library
Case studies, white papers, webinars and platform deep-dives from the scientists doing the work.
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
A new publication by MSD in Organic Process Research & Development details the process development and large-scale manufacturing of the key Northern Fragment of Enlicitide Decanoate.
The rise of GLP-1 receptor agonists as breakthrough treatments for diabetes and obesity has sparked a wave of innovation across the industry. When a clinical-stage biotech company with a…
Every year on Rare Disease Day, patients, families, and researchers join forces to draw attention to the unmet needs of those living with rare diseases. In honor of Rare Disease Day 2025, we…
A Comparison of 11-Monomer PNA synthesis: Literature Protocol vs. Our Enhanced Method
The growing need for oligonucleotide therapeutics aimed at larger patient populations has driven the demand for high-quality nucleoside phosphoramidite which are building blocks for…
Download and View Poster
Abstract: A biotech company engaged WuXi TIDES to develop a siRNA-GalNAc drug candidate for cardiovascular disease. The original synthesis process for this 23-mer siRNA resulted in a yield…
In this case study, we demonstrated a project in which the WuXi TIDES peptide team successfully enabled a challenging RDC to IND filing in three months. Leveraging our extensive expertise…
Prev PREVIOUS ARTICLE
Prev PREVIOUS ARTICLE
WuXi STA is proceeding with a major multi-site, global expansion plan to enhance its manufacturing capabilities and capacities. Yu Lu, the Chief Business Officer of WuXi STA and Head of WuXi…
The phenoxyacetyl (pac) base protection has been adopted in oligonucleotide synthesis to enable utilization of milder deprotection conditions suitable for base-sensitive nucleic…
Prev PREVIOUS ARTICLE
Prev PREVIOUS ARTICLE
In today’s oligonucleotide therapeutic development, to make oligonucleotides “druggable” with enhanced PK/PD properties has always been the focus. There are several promising approaches.…
Introduction: In 2021, a biotech company was developing a vaccine that needed large scale oligonucleotide production capacity and rapid turnaround to produce hundreds of kilo oligonucleotide…
Small interfering RNA therapeutics are advanced oligonucleotide therapy. WuXi STA oligonucleotide CRDMO platform provides the integrated solution for siRNA candidates.
WuXi STA has built an integrated new modality CRDMO platform with our experienced oligonucleotide and peptide teams. This video demonstrated an example of our integrated platform…
The integrated peptide platform of WuXi STA offered parallel streamlines which enabled this PDC project completed in 9 months
PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. PDCs combine peptides and linker-toxins,…
An efficient method was developed to purge the heavy metal and control the residue at low level in final G-Quadruplexes oligonucleotide.
We’d like to invite you to join a virtual tour of our oligonucleotide facilities at WuXi TIDES. Please contact us for the full tour.
Prev PREVIOUS ARTICLE
Prev PREVIOUS ARTICLE
Prev PREVIOUS ARTICLE
This two-part webinar series explores recent developments in oligonucleotide chemistry, biology, DMPK, toxicological assessment, manufacture, and formulation.
This two-part webinar series explores recent developments in oligonucleotide chemistry, biology, DMPK, toxicological assessment, manufacture, and formulation.
This video demonstrate WuXi TIDES unique peptide CRDMO platform, state-of-the-art facility R&D labs, API & drug product manufacturing plants.
In this article, we will look specifically at the development challenge faced when moving a peptide-drug conjugate (PDC) from pre-clinical (gram-scale) to phase I (kg-scale). New modality…
Prev PREVIOUS ARTICLE
WuXi STA’s William Fang, Vice President and Head of New Modalities Oligo & Peptide, discussed trends in oligonucleotide drug development in this virtual panel discussion published in the…
Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. Dive into the video to learn…
Do you have peptide drug candidates in development? Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director, Biopharmaceutical Development and Manufacturing at Neuraly and…
Watch this webinar presented by Graham Ogg, Professor, MRC Weatherall Institute of Molecular Medicine, University of Oxford and Hui Liao, Director, Peptide Discover Service, WuXi STA
Prev PREVIOUS ARTICLE
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA
